A functional polymorphism T309G in MDM2 gene promoter, intensified by Helicobacter pylori lipopolysaccharide, is associated with both an increased susceptibility and poor prognosis of gastric carcinoma in Chinese patients

BMC Cancer

Xiaolin Pan³  Yuqin Li³  Jin Feng¹  Xiaoyong Wang²  Bo Hao³  Ruihua Shi³  Guoxin Zhang³ 

[1] Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China

[2] Department of Gastroenterology, Changzhou No.2 People’s Hospital, Affiliated with Nanjing Medical University, Changzhou 213000, China

[3] Department of Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

关键词: Lipopolysaccharide;    SNP;    MDM2;    Gastric carcinoma;    Helicobacter pylori;   

Others  :  1079864
DOI  :  10.1186/1471-2407-13-126

 received in 2012-11-17, accepted in 2013-03-04,  发布年份 2013

【 摘 要 】

Background

Studies on the association between MDM2 SNP309 (T > G) and gastric cancer have reported conflicting results. Thus, the aim of this study was to investigate whether MDM2 SNP309 is associated with susceptibility and prognosis of gastric carcinoma in Chinese patients.

Methods

Total of 574 gastric carcinoma cases and 574 age- and sex-matched healthy controls were included. MDM2 polymorphism was detected by PCR- RFLP and infection of Helicobacter pylori (H. pylori) by a validated serology test. The functionality of MDM2 SNP309, with or without H. pylori lipopolysaccharide (LPS), was examined by dual-luciferase assay. Kaplan-Meier survival curves were used to evaluate survival. Additional, a meta-analysis was conducted to verity the findings.

Results

MDM2 SNP309G/G genotype was associated with an increased risk of gastric carcinoma when compared with T/T genotype or T carriers (both P < 0.01), and a joint effect between MDM2 SNP309G/G and H. pylori infection was observed to intensify gastric carcinoma risk. SNP309G/G was identified as an independent marker of poor overall survival of carcinoma. In vitro, the luciferase assay further showed an increased transcriptional activity of SNP309G allele compared with SNP309T allele, and the function of polymorphism T309G in MDM2 gene promoter was intensified by H. pylori LPS. Pooled results from the meta-analysis confirmed that SNP309G/G genotype had a significantly increased risk of gastric carcinoma compared with T/T genotype or T carriers, consistent with the case–control findings.

Conclusions

MDM2 SNP309G allele is associated with an increased risk and poor prognosis of gastric carcinoma in Chinese patients. Additional, there is a joint effect of MDM2 SNP309G/G allele and H. pylori infection on gastric carcinoma development, which may attribute to H. pylori LPS.

【 授权许可】

   
2013 Pan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Jin S, Levine AJ: The p53 functional circuit. J Cell Sci 2001, 114:4139-4140.
• [2]Soussi T, Lozano G: p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 2005, 331:834-842.
• [3]Iwakuma T, Lozano G: MDM2, an introduction. Mol Cancer Res 2003, 1:993-1000.
• [4]Lozano G: Mouse models of p53 functions. Cold Spring Harb Perspect Biol 2010, 2:a001115.
• [5]Chen J, Wu X, Lin J, Levine AJ: mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 1996, 16:2445-2452.
• [6]Haupt Y, Barak Y, Oren M: Cell type-specific inhibition of p53-mediated apoptosis by MDM2. EMBO J 1996, 15:1596-1606.
• [7]Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602.
• [8]Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ: MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006, 66:5104-5110.
• [9]Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX, Kawabe T, Omata M: MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 2006, 12:4867-4871.
• [10]Grochola LF, Müller TH, Bond GL, Taubert H, Udelnow A, Würl P: MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation. Pancreas 2010, 39:76-80.
• [11]Yarden RI, Friedman E, Metsuyanim S, Olender T, Ben-Asher E, Papa MZ: MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast Cancer Res Treat 2008, 111:497-504.
• [12]Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK: Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991, 325:1127-1131.
• [13]Haruma K, Komoto K, Kamada T, Ito M, Kitadai Y, Yoshihara M, Sumii K, Kajiyama G: Helicobacter pylori infection is a major risk factor for gastric carcinoma in young patients. Scand J Gastroenterol 2000, 35:255-259.
• [14]Cover TL, Blaser MJ: Helicobacter pylori in health and disease. Gastroenterology 2009, 136:1863-1873.
• [15]Reeves EP, Ali T, Leonard P, Hearty S, O’Kennedy R, May FE, Westley BR, Josenhans C, Rust M, Suerbaum S, Smith A, Drumm B, Clyne M: Helicobacter pylori lipopolysaccharide interacts with TFF1 in a pH-dependent manner. Gastroenterology 2008, 135:2043-2054. 2054. e1-2
• [16]Chochi K, Ichikura T, Kinosthita M, Majima T, Shinomiya N, Tsujimoto H, Kawabata T, Sugasawa H, Ono S, Seki S, Mochizuki H: Helicobacter pylori augments growth of gastric cancers via the lipopolysaccharide-toll-like receptor 4 pathway whereas its lipopolysaccharide attenuates antitumor activities of human mononuclear cells. Clin Cancer Res 2008, 14:2909-2917.
• [17]Yokota S, Okabayashi T, Rehli M, Fujii N, Amano K: Helicobacter pylori lipopolysaccharides upregulate toll-like receptor 4 expression and proliferation of gastric epithelial cells via the MEK1/2-ERK1/2 mitogen-activated protein kinase pathway. Infect Immun 2010, 78:468-476.
• [18]Peek RM Jr, Crabtree JE: Helicobacter infection and gastric neoplasia. J Pathol 2006, 208:233-248.
• [19]Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H: MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006, 24:4434-4440.
• [20]Yang M, Guo Y, Zhang X, Miao X, Tan W, Sun T, Zhao D, Yu D, Liu J, Lin D: Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 2007, 28:1996-2001.
• [21]Cao YY, Zhang XF, Guo W, Wang R, Ge H, Zhang JH: Association of the MDM2 polymorphisms with susceptibility of esophageal squamous cell carcinoma and that of gastric cardiac adenocarcinoma. Tumor 2007, 8:628-632.
• [22]Cho YG, Choi BJ, Song JH, Kim CJ, Cao Z, Nam SW, Lee JY, Park WS: No association of MDM2 T309G polymorphism with susceptibility to Korean gastric cancer patients. Neoplasma 2008, 55:256-260.
• [23]Wang X, Yang J, Ho B, Yang Y, Huang Z, Zhang Z, Zhang G: Interaction of Helicobacter pylori with genetic variants in the MDM2 promoter is associated with gastric cancer susceptibility in Chinese patients. Helicobacter 2009, 14:114-119.
• [24]Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: eds: American Joint Committee on Cancer Staging Manual. 7th edition. New York: Springer; 2009.
• [25]Lauren P: The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965, 64:31-49.
• [26]Wang XY, Yang Y, Shi RH, Ho B, Wang HD, Zhang GX: An evaluation of a serologic test with a current infection marker of Helicobacter pylori before and after eradication therapy in Chinese. Helicobacter 2008, 13:49-55.
• [27]Prendergast MM, Kosunen TU, Moran AP: Development of an immunoassay for rapid detection of ganglioside GM(1) mimicry in Campylobacter jejuni strains. J Clin Microbiol 2001, 39:1494-1500.
• [28]Lee CH, Tsai CM: Quantification of bacterial lipopolysaccharides by the purpald assay: measuring formaldehyde generated from 2-keto-3-deoxyoctonate and heptose at the inner core by periodate oxidation. Anal Biochem 1999, 267:161-168.
• [29]Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22:719-748.
• [30]DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
• [31]Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
• [32]Schmidt MK, Tommiska J, Broeks A, van Leeuwen FE, Van’t Veer LJ, Pharoah PD, Easton DF, Shah M, Humphreys M, Dörk T, Reincke SA, Fagerholm R, Blomqvist C, Nevanlinna H: Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast Cancer Res 2009, 11:R89. BioMed Central Full Text
• [33]Han JY, Lee GK, Jang DH, Lee SY, Lee JS: Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 2008, 113:799-807.
• [34]Gryshchenko I, Hofbauer S, Stoecher M, Daniel PT, Steurer M, Gaiger A, Eigenberger K, Greil R, Tinhofer I: MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol 2008, 26:2252-2257.
• [35]Shikata K, Doi Y, Yonemoto K, Arima H, Ninomiya T, Kubo M, Tanizaki Y, Matsumoto T, Iida M, Kiyohara Y: Population-based prospective study of the combined influence of cigarette smoking and Helicobacter pylori infection on gastric cancer incidence: the Hisayama Study. Am J Epidemiol 2008, 168:1409-1415.
• [36]Huang JQ, Sridhar S, Chen Y, Hunt RH: Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998, 114:1169-1179.
• [37]Blaser MJ, Parsonnet J: Parasitism by the “slow” bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. J Clin Invest 1994, 94:4-8.
• [38]Kodama M, Fujioka T, Murakami K, Okimoto T, Sato R, Watanabe K, Nasu M: Eradication of Helicobacter pylori reduced the immunohistochemical detection of p53 and MDM2 in gastric mucosa. J Gastroenterol Hepatol 2005, 20:941-946.
• [39]Nakajima N, Ito Y, Yokoyama K, Uno A, Kinukawa N, Nemoto N, Moriyama M: The Expression of Murine Double Minute 2 (MDM2) on Helicobacter pylori-Infected Intestinal Metaplasia and Gastric Cancer. J Clin Biochem Nutr 2009, 44:196-202.
• [40]Wei J, Nagy TA, Vilgelm A, Zaika E, Ogden SR, Romero-Gallo J, Piazuelo MB, Correa P, Washington MK, El-Rifai W, Peek RM, Zaika A: Regulation of p53 tumor suppressor by Helicobacter pylori in gastric epithelial cells. Gastroenterology 2010, 139:1333-1343.
• [41]Shibata A, Parsonnet J, Longacre TA, Garcia MI, Puligandla B, Davis RE, Vogelman JH, Orentreich N, Habel LA: CagA status of Helicobacter pylori infection and p53 gene mutations in gastric adenocarcinoma. Carcinogenesis 2002, 23:419-424.
• [42]Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH: Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003, 125:1636-1644.
• [43]Parsonnet J, Friedman GD, Orentreich N, Vogelman H: Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997, 40:297-301.
• [44]Wen S, Moss SF: Helicobacter pylori virulence factors in gastric carcinogenesis. Cancer Lett 2009, 282:1-8.
• [45]Ogawa T, Asai Y, Sakai Y, Oikawa M, Fukase K, Suda Y, Kusumoto S, Tamura T: Endotoxic and immunobiological activities of a chemically synthesized lipid A of Helicobacter pylori strain 206–1. FEMS Immunol Med Microbiol 2003, 36:1-7.
• [46]Matsuyama N, Kirikae T, Kirikae F, Hashimoto M, Amanot K, Hayashi S, Hirai Y, Kubota T, Nakano M: Non-standard biological activities of lipopolysaccharide from Helicobacter pylori. J Med Microbiol 2001, 50:865-869.